| 摘要 |
NEW MATERIAL:A rhodomycin group antibiotic derivative shown by the formula I [combinations of R1, R2, R3 and R4 are a) H, a group shown by the formula II, carbomethoxy, and OH, b) OH, the group shown by the formula II, carbomethoxy, and OH, c) H, the group shown by the formula II, OH, and OH, d) H, H, the group shown by the formula II, and OH, e) H, H, the group shown by the formula II, and OH, and f) OH, the group shown by the formula II, OH and H], epsilon- rhodomycin RDC, epsilon-isorhodomycin RDC, beta-rhodomycin RDC, gamma-rhodomycin RDC, gamma-rhodomycin RDRS, beta-pyromycin RDC (R is sugar residue of rodosamin; D is sugar residue of deoxyfucose; C is sugar residue of rhodinose; RS is sugar residue of cynerulose) or its acid addition salt. USE:A carcinostatic agent. PROCESS:A rhodomycinone aglycone shown by the formula III is added to a cultured solution of Streptomyces galilaeus KE303 (FEPM-P No.4808) and subjected to bacterium exchange to give the titled antibiotic. |
